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183 Inhibition of lipopolysaccharide signalling by LL-37 and
repercussions for LL-37 function in the Pseudomonas-infected
cystic ﬁbrosis lung
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University Belfast, Medicine, Dentistry and Biomedical Science, Belfast, United
Kingdom; 2Queens University Belfast, Pharmacy, Belfast, United Kingdom
Human cathelicidin, LL-37, a 37 amino acid antimicrobial peptide produced by
neutrophils and respiratory epithelium, has been shown to possess immunomod-
ulatory properties. Mechanisms of action to explain LL-37’s anti-inﬂammatory
activity continue to be elucidated, with a number of publications suggesting
potential intracellular targets in addition to extracellular lipopolysaccharide (LPS)
and lipotechoic acid (LTA) binding and neutralisation. Therefore, we investigated
the effect of LL-37 on LPS signalling pathways in human monocytes. In response
to LPS stimulation pre-treatment of monocytic cells with LL-37 inhibited NF-úB
activation, STAT-1 and AP-1 signalling pathways. Washing of cells to remove LL-37
abolished any subsequent effects on LPS signalling indicating that LL-37’s effects
on LPS signalling were mediated extracellularly most likely via direct neutralisation
of LPS. We also examined the status of LL-37 in sputa from patients with cystic
ﬁbrosis (CF). LL-37 levels were found to be higher in uninfected in comparison to
Pseudomonas aeruginosa-infected sputa, contrary to expected results, but explained
by the signiﬁcantly higher levels of glycosaminoglycans present in infected samples
compared to uninfected. Treatment of these samples with a combination of Dornase
alpha and Lyases proved effective in liberating bound LL-37 in infected samples
only whilst uninfected samples remained unchanged. Our results suggest that the
main mechanism by which LL-37 exerts its immunomodulatory effects on LPS-
induced cytokine production is by binding directly to LPS a process which is
diminished during Pseudomonas infection in CF lung.
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Human chitotriosidase (Chit) is a member of the chitinose family, mainly secreted
by activated macrophages and, to a lesser degree, by neutrophils. Chit is markedly
increased in pts with lysosomal storage diseases, and, even if to a lesser extent, in
other diseases in which an abnormal inﬁammatory pattern is described.
In this study we investigated whether Chit is augmented in the plasma of CF pts
and if it can be a useful marker for inﬂammatory status in the disease. Serum Chit
activity determination was performed, according to Hollak (1994), in 46 CF pts
(18 females, mean age 21 yrs, range 1−48, mean FEV1 64% pr, range 22–129).
Mean chitotriosidase value was 54.45 nmol/ml/h ±38, higher than the mean value
in healthy control group (25.75±17). As in the general population in the 6% of
CF pts Chit dosage showed no activity. Chit activity showed no statistical difference
in 13 pts with elevated PCR versus 18 pts with normal PCR (64.87, 17.6–209.6
and 42.5, 10.4–104.8 respectively), in the dosage pre- and post e.v. treatment in
11pts (72.5, 20−100 and 52.36, 25−101 respectively) and in 14 pts with normal
PCR and FEV150%pr versus 10 pts with normal PCR and FEV1< 50% (48.14,
12−104.8 versus 52.32, 1.6−101.6 respectively). Chit activity in 8 pts younger than
15 yrs with normal PCR resulted lower, even if not signiﬁcantly, than in 6 pts older
than 15 yrs with normal PCR (34.45, 10.4–75.6 and 57.71, 25.6–101.6 respectively.
p = 0.087).
In conclusion Chit activity in CF resulted slighly increased than in nomal controls.
It seems to have a better correlation with the age of the patient than with the degree
of the BPN and with the presence of a acute exacerbation.
185 Characterization of piperacillin-speciﬁc T-cell clones from
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Piperacillin (PIP) exposure in patients with cystic ﬁbrosis is associated with
a high incidence of delayed-type hypersensitivity reactions. In this study, the
nature of the PIP-speciﬁc T-cell response was delineated by means of in vitro
stimulation of lymphocytes and T-cell clones. The four patients each developed
maculopapular exanthema and fever (+/− arthralgia or ﬂu-like symptoms) following
PIP exposure. Lymphocytes were isolated and incubated with piperacillin for
6 days. Proliferation was measured by addition of [3H]thymidine. T-cells from
responding cultures were cloned by serial dilution to evaluate their phenotype,
function (proliferation, cytokine secretion, and cytolytic activity), mechanism of
antigen presentation and cross reactivity with nine structurally related compounds.
Lymphocytes were stimulated to proliferate with PIP and PIP-modiﬁed serum
albumin ([control; 803±250 cpm], [PIP 2 mM; 4554±438 cpm]). Lymphocytes
from non-hypersensitive patients were not stimulated ([C; 465.3±310 rpm], [PIP
2mM; 670.2±489.5 rpm]). CD4+, CD8+, and CD4+CD8+ T-cell clones, which
proliferated, killed target cells and secreted high levels of IL4, IL5, IFN-g,
and MIP-1b following PIP or PIP-albumin stimulation, were generated from the
hypersensitive patients. The proliferative response was
1. highly speciﬁc in terms of drug structure − T-cells were stimulated with PIP,
but not structurally-related drugs; and
2. dependent on drug-protein conjugation. These data indicate that T cells re-
sponsive towards the PIP protein conjugates are present in the circulation of
hypersensitive patients.
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Oxidative status has a role in the progressive lung damage in CF. Glutathione is an
important antioxidant agent and cysteine is the amino-acid that gives to glutathione
the antioxidant status. We investigated if oral cysteine has an impact on oxidative
status and respiratory function in CF. Oxidative status, estimated on serum d-ROM
test and BAP test, and FEV1%pr were performed in 71 pts in which oral whey
protein isolate with high content of cysteine (PROther®) was prescribed. All pts
showed basal pathological oxidative status (d-ROM mean value: 402 U-CARR,
range 223–647 versus normal range 250–300; BAP test mean value 2479mmol/L,
range 1746–3225 versus normal value >2200) and FEV1< 70% pr. Improvement
in oxidative status, even if not signiﬁcantly, was observed in the 46 pts which
completed 6 months of therapy (mean d-ROM test value 391 U-CARR before
therapy and 362 after therapy; BAP test value 2621 mmol/L before therapy and
2835 after therapy) and in the 42 pts which completed 12 months of therapy (mean
d-ROM test value 365 U-CARR before therapy and 421 after therapy; mean BAP
test value 2400mmol/L before therapy and 2800 after therapy). Beta regression
coefﬁcient of FEV1%pr/yr in 66 pts after PROther® supplementation was −0.1
FEV1%pr/yr as mean value (range −12.4, +13.7) and −0.6 FEV1%pr/yr as median
value. In 27 pts/66 FEV1%pr improved. Five patients showed no compliance to
the treatment. No adverse effect has been reported. Oral addition of cysteine in CF
pts is well accepted and tolerated. It seems efﬁcacious to improve oxidative status
and, in our data, beta regression coefﬁcient of FEV1%pr/yr is lower than that one
normal observed in literature for CF pts.
